Yes, so long as the patient was able to tolerate the treatment and kept to strict dose intervals, then results looked pretty good (very small sample size - 4). The data presented is a little unclear, but shows promise.
The issue with tolerability lead them to develop a gel formulation for future burns trials, which has been used under the SAS with great results so far (the cases they've chosen to present anyway).
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-26
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
0.015(2.94%) |
Mkt cap ! $121.5M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 52.5¢ | 51.0¢ | $36.12K | 69.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15185 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 27041 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |